Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 1/2009

01-11-2009 | Introduction

Toward a New Understanding of Attention-Deficit Hyperactivity Disorder

Advances in Research and Treatment

Author: Thomas J. Spencer

Published in: CNS Drugs | Special Issue 1/2009

Login to get access

Excerpt

Our understanding of attention-deficit hyperactivity disorder (ADHD), its underlying nature and its treatment have expanded owing to new strides made in basic and clinical research. This supplement comprises four articles, each focusing on an area that has shown significant developments in recent years: (1) the diagnostic and therapeutic challenges presented by patients who have ADHD and comorbid disorders; (2) efficacy, safety and patient selection issues with currently approved pharmacological treatments; (3) advances in defining ADHD neuropathophysiology; and (4) the clinical utility of noradrenergic α2-receptor agonists for managing ADHD symptoms. …
Literature
1.
Busch B, Biederman J, Cohen LG, et al. Correlates of ADHD among children in pediatric and psychiatric clinics. Psychiatr Serv 2002; 53: 1103–11CrossRef
2.
Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996; 53: 437–46CrossRef
3.
Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry 1996; 35: 1193–204CrossRef
4.
Spencer TJ. Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms. CNS Drugs 2009; 23Suppl. 1: 9–20CrossRef
5.
Biederman J, Wilens T, Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152: 1652–8CrossRef
6.
Biederman J, Petty CR, Dolan C, et al. The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study. Psychol Med 2008; 21: 1–10
7.
Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 1119–27CrossRef
8.
Santosh PJ, Baird G, Pityaratstian N, et al. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 2006; 32: 575–83CrossRef
9.
Scheffer RE, Kowatch RA, Carmody T, et al. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005; 162: 58–64CrossRef
10.
Newcorn JH, Kratochvil CJ, Allen AJ, et al., for the Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165: 721–30CrossRef
11.
Adderall XR. Prescribing information. Wayne (PA): Shire Pharmaceuticals, Inc., 2007
12.
Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 2008; 11: 470–81CrossRef
13.
Concerta. Prescribing information. Mountain View (CA): ALZA Corporation, 2007
14.
Adler LA, Barkley RA, Newcorn JH, et al. Managing ADHD in children, adolescents, and adults with comorbid anxiety. J Clin Psychiatry 2007; 68: 451–62CrossRef
15.
Strattera. Prescribing information. Indianapolis (IN): Eli Lilly & Company, 2007
16.
Scahill L, Pachler M. Treatment of hyperactivity in children with pervasive developmental disorders. J Child Adolesc Psychiatr Nurs 2007; 20: 59–62CrossRef
17.
Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009; 23Suppl. 1: 21–31CrossRef
18.
Arnsten AFT. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23Suppl. 1: 33–41CrossRef
19.
Stuss DT, Knight RT. Principles of frontal lobe function. Oxford University Press, Cary, NC, 2002CrossRef
20.
Arnsten AF. Catecholamine and second messenger influences on prefrontal cortical networks of “representational knowledge”: a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex 2007; 17Suppl. 1: i6–15CrossRef
21.
Bobb AJ, Addington AM, Sidransky E, et al. Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 67–72CrossRef
22.
Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1313–23CrossRef
23.
Tahir E, Yazgan Y, Cirakoglu B, et al. Association and linkage of DRD4 and DRD5 with attention deficit hyper-activity disorder (ADHD) in a sample of Turkish children. Mol Psychiatry 2000; 5: 396–404CrossRef
24.
Buschman TJ, Miller EK. Top-down versus bottom-up control of attention in the prefrontal and posterior parietal cortices. Science 2007; 315: 1860–2CrossRef
25.
Knight RT, Staines WR, Swick D, et al. Prefrontal cortex regulates inhibition and excitation in distributed neural networks. Acta Psychol (Amst) 1999; 101: 159–78CrossRef
26.
Scahill L. Alpha-2 Adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009; 23Suppl. 1: 43–49CrossRef
27.
Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121: e73–84CrossRef
28.
Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 1551–9CrossRef
29.
Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 50–4CrossRef
30.
Palumbo DR, Sallee FR, Pelham Jr WE, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47: 180–8CrossRef
31.
Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158: 1067–74CrossRef
32.
Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008; 47: 189–98PubMed
33.
Jakala P, Riekkinen M, Sirvio J, et al. Clonidine, but not guanfacine, impairs choice reaction time performance in young healthy volunteers. Neuropsychopharmacology 1999; 21: 495–502CrossRef
34.
Spiegel R, DeVos JE. Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects. Br J Clin Pharmacol 1980; 10Suppl. 1: 165S–8SCrossRef
Metadata
Title
Toward a New Understanding of Attention-Deficit Hyperactivity Disorder
Advances in Research and Treatment
Author
Thomas J. Spencer
Publication date
01-11-2009
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue Special Issue 1/2009
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200923000-00002

Other articles of this Special Issue 1/2009

CNS Drugs 1/2009 Go to the issue

CME Post-test

Post-Test Questions

CME Overview

Advances in Attention-Deficit Hyperactivity Disorder Treatment

Review Article

Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults

Review Article

Alpha-2 Adrenergic Agonists in Children with Inattention, Hyperactivity and Impulsiveness

Evaluation Form

Advances in ADHD Treatment: A Focus on the Role of Noradrenergic and Alpha-2a Receptor Modulation

Review Article

Issues in the Management of Patients with Complex Attention-Deficit Hyperactivity Disorder Symptoms